linjc16/ctgov huggingface dataset:
The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock

Study Overview
=================
Brief Summary
-----------------
Currently, bedside ultrasound (US) is performed routinely in emergency department (ED) patients with undifferentiated shock to help guide resuscitation. Previously, it has never been possible to measure cardiac output on patients in the ED. Our clinical question looks at whether the USCOM device gives clinically relevant information in addition to ED cardiac US in patients with shock.

Official Title
-----------------
The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock

Conditions
-----------------
Shock

Intervention / Treatment
-----------------
* Device: USCOM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in shock, as defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9 Exclusion Criteria: less than 18 years old Pregnant Patients in shock due to trauma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Shock<br>Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9 | Device: USCOM<br>* The USCOM device will be used in addition to cardiac ultrasound in patients with shock.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac Output | Cardiac ultrasound findings will be compared to cardiac index and output from the USCOM device | Twice during ED visit, averaging one hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient outcomes | Data will be collected on outcomes of patients including death, length of ICU stay, length of hospital stay, and diagnosis. | After emergency department visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shock, USCOM, Cardiac Ultrasound, Emergency Department
Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to establish the diagnostic value of O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET-CT, [18F]-fluorocholine (FCH) and magnetic resonance imaging (MRI) combined with magnetic resonance spectroscopy (MRS) in patients with suspected cerebral glioma using neuronavigated biopsies with histopathological analysis as reference.

Detailed Description
-----------------
The objectives of the study are: To demonstrate if the multimodal approach, combining the morphological aspect of the MRI with the metabolic aspect of the tumor with magnetic resonance spectroscopy (MRS) and O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) or 18F]-fluorocholine (FCH) PET/CTthe FCH allows to improve the location of a active metabolic tumor and its impact on the ideal choice of sampling biopsy. To underline the differences and similarities between MRS and 18F]-fluorocholine PET / CT in the assessment of metabolism of the choline. To establish the diagnosis value of both methods, separately and in combination. To determine which examinations are useful and complementary for the diagnosis and the management of gliomes. FET combined with MRS may be a powerful, widely applicable new method to improve the diagnosis of cerebral gliomas. The extent to which FCH and MRS provide similar information is not known precisely and this study will establish their respective diagnostic value in differentiating tumoral from non-tumoral tissue.

Official Title
-----------------
Impact of Multimodal Diagnostic Assessment of Cerebral Gliomas With F-18-fluoroethyl-L-tyrosine PET/CT, F-18-fluorocholine PET/CT and Magnetic Resonance Imaging and Spectroscopy

Conditions
-----------------
Glioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspicion of intracerebral glioma on MR Men of women Age >18, no upper limit as long as a biopsy or intervention is foreseen Exclusion Criteria: Need of rapid intervention in <2 weeks Previous neurosurgical intervention (biopsy, shunt, etc.) or any other cerebral treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability of image-guided biopsy using FET, FCH PET/CT and MRS information to target the most representative sites of tumor grade as compared to histopathological examination |  | On the biopsy day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glioma, diagnosis, Imaging, Positron emission tomography, Magnetic resonance imaging, Magnetic resonance spectroscopy
The Effect of Neuromuscular Electrical Stimulation

Study Overview
=================
Brief Summary
-----------------
The effect of neuromuscular electrical stimulation on muscle atrophy in sedated patients on intensive care was studied. The aim of this study was to explore if electrical stimulation could prevent muscle atrophy.

Detailed Description
-----------------
Patients were included in the study one day after administration when prolonged sedation and ventilation were expected. They were divided into intervention (n=7) and control (n=14) groups. For the intervention group, an intermittent neuromuscular electrical stimulation was applied daily for 30 minutes on the right thigh whereas the left thigh was used as a control. Heart rate, respiration rate, systolic and diastolic blood pressure and oxygen saturation were monitored before, during and after the electrostimulation. Perimeter of the right and left thighs was measured in both groups every 3 days at 5 cm above the upper edge of the kneecap.

Official Title
-----------------
on Muscle Wasting in Artificially Ventilated and Sedated Patients at the Intensive Care Unit: a Pilot Study

Conditions
-----------------
Postoperative Coronary Artery Bypass Grafting (CABG), Chronic Obstructive Pulmonary Disease (COPD), Ventilatory Failure

Intervention / Treatment
-----------------
* Device: ELECTRICAL STIMULATION


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: . Prior to inclusion in the study, an informed consent was given by the family of the patients which was approved by the local Ethics Committee of the Virga Jesse Hospital and was performed in accordance with the standards of the 1964 Declaration of Helsinki. Exclusion Criteria: Patients were excluded from the study if they were still able to move their limb actively in spite of the sedation. Patients were also excluded if they had signs of recent ischemia or infarction for less then seven days. Patients with severe orthopaedic or vascular damage, i.e., fractures or oedema in the lower limbs were also excluded. Patients with an augmented risk for neuro electrical stimulation such as open wounds, hemodialysis or an arterial catheter at the stimulation area were also excluded.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ELECTRICAL STIMULATION|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perimeter of the right and left thighs was measured in both groups every 3 days at 5 cm above the upp |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Functional electrical stimulation, muscular atrophy, intensive care
Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack.

Study Overview
=================
Brief Summary
-----------------
Patients with stroke or transient ischemic attach should receive advise on smoking cessation. It is however unknown if an intensive smoking cessation program is better than ordinary advise on smoking cessation during hospitalisation for stroke or transient ischemic attack. The aim of the study was to assess if an intensive smoking cessation program made more patients stop smoking after stroke or transient ischemic attack.

Detailed Description
-----------------
Patients with stroke or transient ischemic attach should receive advise on smoking cessation. It is however unknown if an intensive smoking cessation program is better than ordinary advise on smoking cessation during hospitalisation for stroke or transient ischemic attack. The aim of the study was to assess if an intensive smoking cessation program made more patients stop smoking after stroke or transient ischemic attack. Patients with stroke or transient ischemic attack are admitted to the department of neurology at Odense University hospital. Patient who are smokers on admission and age < 76 years, inhabitants in Funen County and with symptoms developed before admission will be offered participation in the study unless they have severe stroke, stroke more than 3 weeks before admission, other severe disease or unable to participate. Study participants will be randomised to either usual short advise on smoking cessation or an intensive smoking cessation program. All participants will be followed-up for 6 months with regard to smoking habits.

Official Title
-----------------
Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack. A Randomised Controlled Trial

Conditions
-----------------
Stroke, Transient Ischemic Attack

Intervention / Treatment
-----------------
* Behavioral: Smoking cessation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age < 76 years Inhabitant in Funen County Acute stroke or transient ischemic attack Symptoms with onset before admission Current smoker on admission Exclusion Criteria: Severe stroke Current stroke onset more than 3 weeks before admission Other severe disease Unable to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Smoking cessation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking cessation rate |  |  |
Observational Registry on Acute Coronary Syndromes in Campania

Study Overview
=================
Brief Summary
-----------------
This registry aims to collect data related to management of patients affected by acute coronary syndromes and hospitalized in the Campania Region of Italy

Official Title
-----------------
Registro Campano Delle Sindromi Coronariche Acute

Conditions
-----------------
Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized for acute coronary syndromes Exclusion Criteria: Refuse to provide informed consent for study enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  | 1 year |
Anterior Prolift Versus Posterior Prolift for Pelvic Floor Prolapse

Study Overview
=================
Brief Summary
-----------------
Women who had surgery for pelvic floor prolapse underwent surgery by anterior Prolift or Posterior prolift at least a year after the surgery. The data from the charts and from telephone conversations with the patients will be entered to a database. Physical examination data will also be incorporated.

Conditions
-----------------
Pelvic Floor Prolapse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who underwent surgery by anterior Prolift or posterior Prolift for pelvic floor prolapse Exclusion Criteria: Women who did not have surgery by Prolift for pelvic floor prolapse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms of pelvic floor prolapse | We will question the women if they have a feeling of a mass protruding through the labia. Physical examination data will also be incorporated. | One year after surgery |
The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction

Study Overview
=================
Brief Summary
-----------------
This is a multicenter trial comparing laparoscopic correction of a perforated peptic ulcer with the open technique by upper laparotomy. Hypothesis is that after laparoscopic correction will be discharged 3 days sooner due to less postoperative pain and complications.

Detailed Description
-----------------
as written above

Official Title
-----------------
The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction by Upper Laparotomy

Conditions
-----------------
Perforated Peptic Ulcer

Intervention / Treatment
-----------------
* Procedure: laparoscopic surgery
* Procedure: Upper laparotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients clinical suspected for perforated peptic ulcer Exclusion Criteria: Pregnancy Younger than 18 years Unable to sign consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>laparoscopic | Procedure: laparoscopic surgery<br>* laparoscopic correction perforated peptic ulcer<br>|
| Active Comparator: 2<br>open correction | Procedure: Upper laparotomy<br>* upper laparotomy for correction of perforated peptic ulcer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| days of discharge |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative VAs pain score and opiate usage; postoperative complications; Quality of live (RAND 36, euroquol) |  | follow up 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopic, peptic ulcer
123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.

Official Title
-----------------
Outcome Study on BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

Conditions
-----------------
Coronary Disease, Fatty Acids, Unsaturated, Radioisotopes, Hemodialysis, Single Photon Emission Computed Tomography

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Adult hemodialysis patients with one or more of the following 10 risk factors for coronary heart disease Hypertension Diabetes mellitus Hyperlipidemia Obliterative arteriosclerosis in the lower extremities Smoker Family history of juvenile coronary artery disease History of ischemic stroke History of heart failure requiring hospitalization Within 3 months after initiation of hemodialysis therapy Dialysis hypotension Exclusion Criteria:Hemodialysis patients who meet any one of the following conditions will be excluded. Peritoneal dialysis Severe valvular disorder requiring treatment Diagnosis of hypertrophic cardiomyopathy(HCM) or dilated cardiomyopathy(DCM) before start of dialysis History of revascularization(PCI, CABG) or prior diagnosis of myocardial infarction Hypersensitivity to BMIPP or its analogue Judged unsuitable for the study for any other reasons by physicians.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myocardial Free Fatty Acid metabolism, High risk patients, End-stage renal failure, Cardiovascular events, prognosis
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed

Study Overview
=================
Brief Summary
-----------------
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet under Fasting and Fed.

Official Title
-----------------
Randomized, 3-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions Under Fasting and Fed Conditions.

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Lisinopril 40 mg Tablet (Zestril) under fed conditions.
* Drug: Lisinopril 40 mg Tablet under fasting conditions.
* Drug: Lisinopril 40 mg Tablet under fed conditions.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Lisinopril 40 mg Tablet under fed conditions. | Drug: Lisinopril 40 mg Tablet under fed conditions.<br> <br> |
| Active Comparator: 2<br>Lisinopril 40 mg Tablet (Zestril) | Drug: Lisinopril 40 mg Tablet (Zestril) under fed conditions.<br> <br> |
| Experimental: 3<br>Lisinopril 40 mg Tablet under fasting conditions. | Drug: Lisinopril 40 mg Tablet under fasting conditions.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 50 days |
Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection

Study Overview
=================
Brief Summary
-----------------
This study concerns patients having had an infection on their prosthesis (hip, knee,..) and for whom a 2-step exchange of prosthesis has been done. A 2-step exchange consists in explantation of the prosthesis and implementation of a spacer at the first stage, and reimplantation of a new prosthesis in a second stage. Patients with late prosthetic joint infection are at risk for superinfection at the time of reimplantation. The aim is to determine the microbiological epidemiology in patients experiencing failure following reimplantation to establish, based on the drug susceptibilities, which cement could be the most active.

Official Title
-----------------
Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection

Conditions
-----------------
Bone and Joint Infection, Bacterial Infections, EPIDEMIOLOGY

Intervention / Treatment
-----------------
* Other: failure after reimplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with prosthetic joint infection having had a 2-step exchange at least from the reimplantation, between 2013 and 2015. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| failure after reimplantation<br>description of the failure at the reimplantation | Other: failure after reimplantation<br>* description of cinical and microbiological failure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of treatment failure | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of bacteria involved in microbiological failure | description of microbiological failure : bacteria responsible of microbiological failure | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| rate of clinical failure | description of clinical failure | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |